Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLChristin Schütz, Andreas Burchert, Stefan Hanzel et al.|Leukemia|2017Cited by 106
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLStephan Metzelder, Andreas Burchert, Christian Michel et al.|Leukemia|2015Cited by 52
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid LeukemiaSabrina Inselmann, Andreas Burchert, Ying Wang et al.|Cancer Research|2018Cited by 21
Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski TrialAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|Blood|2015Cited by 9
BCR-ABL-Induced Transcriptional Repression of the Interferon Regulatory Factor 8 (IRF-8/ICSBP) Leads to Depletion of Plasmocytoid Dendritic Cells (PDC), Which May Contribute to Leukemogenesis in a Murine Model of Chronic Myeloid LeukemiaSabrina Inselmann, Andreas Burchert, Simone Liebler et al.|Blood|2012Cited by 1